Aetna modified CPB 0525 for lipid disorder screening, effective November 27, 2025. Here's what billing teams need to know about covered and excluded indications under this updated coverage policy.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0525 to clarify medical necessity criteria for lipid panel testing. CPB 0525 directly governs reimbursement for CPT codes 80061, 82465, 83718, 83721, 84478, and 83719. If your lab or practice bills lipid screening for Aetna members, this policy change sets the rules for what gets paid and what gets denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Screening for Lipid Disorders — CPB 0525 |
| Policy Code | CPB 0525 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | Medium |
| Specialties Affected | Primary care, internal medicine, endocrinology, cardiology, clinical laboratory |
| Key Action | Audit your CPT 83721 (direct LDL-C) claims — coverage now requires a confirmed diagnosis of type 2 diabetes or triglycerides above 250 mg/dL |
Aetna Lipid Disorder Screening Coverage Criteria and Medical Necessity Requirements 2025
The Aetna lipid disorder screening coverage policy draws a clear line between what's medically necessary and what it considers experimental. The distinction comes down to patient diagnosis — specifically whether type 2 diabetes or hypertriglyceridemia is documented.
Here's what Aetna considers medically necessary:
Direct LDL-C measurement (CPT 83721) is covered only when the member has triglyceride levels greater than 250 mg/dL or a confirmed diagnosis of type 2 diabetes (ICD-10 range E08.00–E13.9). Without one of those diagnoses on the claim, Aetna will deny direct LDL-C measurement as experimental. This is the sharpest edge in this coverage policy.
Serum triglycerides (CPT 84478) are covered for both screening and diagnosis of lipid abnormalities. No additional diagnosis restriction is listed.
Total serum cholesterol (CPT 82465) and HDL-C (CPT 83718) are both covered for screening and diagnosis of lipid abnormalities. The standard lipid panel (CPT 80061) bundles these components and is covered when selection criteria are met.
That distinction controls how you code the encounter — screening diagnosis Z13.220 versus an active diagnosis code like E78.1 or E78.2. Cholesterol screening for asymptomatic members is not covered if the member's plan excludes preventive services. Diagnostic testing, however, is covered when medically necessary regardless of the preventive services benefit. Verify prior authorization requirements directly with Aetna — CPB 0525 does not address PA requirements.
The real issue here is CPT 83721. Labs and practices routinely run direct LDL-C on virtually every lipid panel. Under this coverage policy, billing 83721 without a supporting type 2 diabetes or hypertriglyceridemia diagnosis is a claim denial waiting to happen. Check your ordering workflows now, before November 27, 2025.
Aetna Lipid Disorder Screening Exclusions and Non-Covered Indications
Aetna's exclusion list in CPB 0525 is specific. These procedures are classified as experimental, investigational, or unproven — meaning no coverage, no exceptions.
Direct LDL-C (CPT 83721) in patients without type 2 diabetes or hypertriglyceridemia is explicitly excluded. This is not a gray area. If the patient's chart doesn't support one of those two diagnoses, the test is not covered under this policy.
Direct VLDL cholesterol measurement (CPT 83719) is excluded for all indications listed in the CPB. Aetna's position is that direct VLDL measurement lacks established clinical effectiveness. Bill 83719 for Aetna members and you're billing against the policy.
Two additional exclusions aren't CPT-code-driven but matter operationally:
| # | Excluded Procedure |
|---|---|
| 1 | Breath isoprene measurements for lipid disorder screening or therapy monitoring — not covered. These point-of-care breath tests have not cleared Aetna's clinical effectiveness bar. |
| 2 | Cholesterol skin testing to predict coronary heart disease risk — not covered. Aetna does not recognize this as a valid screening approach. |
These last two rarely appear in standard lab billing, but if your practice uses any novel lipid screening tools, verify they aren't running against this policy before billing.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Direct LDL-C — triglycerides > 250 mg/dL | Covered | CPT 83721, ICD-10 E78.1 | Hypertriglyceridemia diagnosis required |
| Direct LDL-C — type 2 diabetes | Covered | CPT 83721, ICD-10 E08.00–E13.9 | Diabetes diagnosis required |
| Serum triglycerides — screening/diagnosis | Covered | CPT 84478, ICD-10 Z13.220, E78.1, E78.2 | No additional restriction noted |
| Total serum cholesterol — screening/diagnosis | Covered | CPT 82465, ICD-10 Z13.220 | Not covered if plan excludes preventive services for screening encounters |
| HDL-C — screening/diagnosis | Covered | CPT 83718, ICD-10 Z13.220 | Not covered if plan excludes preventive services for screening encounters |
| Lipid panel (bundled) | Covered | CPT 80061 | Selection criteria must be met for all components |
| Direct LDL-C — no type 2 diabetes, no hypertriglyceridemia | Experimental | CPT 83721 | Claim denial expected without qualifying diagnosis |
| Direct VLDL cholesterol | Not Covered | CPT 83719 | Excluded for all indications in CPB 0525 |
| Breath isoprene measurement | Experimental | No CPT listed | Not covered for screening or therapy monitoring |
| Cholesterol skin testing | Experimental | No CPT listed | Not covered for coronary heart disease risk prediction |
Aetna Lipid Disorder Screening Billing Guidelines and Action Items 2025
These are not suggestions. Each one addresses a specific exposure point in CPB 0525.
| # | Action Item |
|---|---|
| 1 | Audit your CPT 83721 charge capture before November 27, 2025. Pull claims from the past 90 days where you billed direct LDL-C for Aetna members. If those claims don't pair with E08.00–E13.9 (type 2 diabetes) or a documented triglyceride level above 250 mg/dL, you have a denial risk problem that starts on the effective date. |
| 2 | Stop billing CPT 83719 for Aetna members. Direct VLDL measurement is excluded for all indications under CPB 0525. There's no qualifying diagnosis that unlocks coverage. Remove it from your Aetna charge capture or flag it as non-billable to this payer. |
| 3 | Review your financial disclosure process for CPT 83721 in low-risk patients. When a provider orders direct LDL-C for a patient without type 2 diabetes or triglycerides above 250 mg/dL, follow your standard financial responsibility disclosure process before the test runs. This protects your practice from writing off the charge entirely. |
| 4 | Train your coders on the screening vs. diagnostic split. When you bill Z13.220 for an asymptomatic screening encounter, coverage depends entirely on whether the member's plan includes preventive services. When you bill an active diagnosis — E78.1, E78.2, or a diabetes code — diagnostic testing is covered regardless of the preventive benefit. Your coders need to know which bucket each claim falls into. |
| 5 | Check your lipid panel (CPT 80061) build. The standard lipid panel bundles total cholesterol, HDL-C, and triglycerides — all covered under this policy. The issue is when labs add-on direct LDL-C (83721) as a separate line. That add-on requires the qualifying diagnosis. Verify your lab's order-to-bill mapping doesn't automatically attach 83721 without diagnosis validation. |
| 6 | Flag CPB 0381 as a related policy to review. Aetna cross-references CPB 0381 (Cardiovascular Disease Risk Tests) in this bulletin. If your practice bills expanded cardiovascular risk panels alongside lipid screening, review CPB 0381 before assuming coverage carries over. Policies interact, and a denial on one can cascade to another. |
If you're unsure how this policy applies to your specific patient mix or lab billing setup, talk to your compliance officer before November 27, 2025.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Lipid Disorder Screening Under CPB 0525
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 80061 | CPT | Lipid panel |
| 82465 | CPT | Cholesterol, serum or whole blood, total |
| 83718 | CPT | Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) |
| 83721 | CPT | Lipoprotein, direct measurement; LDL cholesterol |
| 84478 | CPT | Triglycerides |
Not Covered / Excluded Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 83719 | CPT | Lipoprotein, direct measurement; VLDL cholesterol | Not covered for any indication listed in CPB 0525 |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| E08.00–E13.9 | Diabetes mellitus (all types — required for CPT 83721 coverage under the type 2 diabetes criterion) |
| E78.1 | Pure hyperglyceridemia (listed in the CPB 0525 source code table) |
| E78.2 | Mixed hyperlipidemia (listed in the CPB 0525 source code table) |
| Z13.220 | Encounter for screening for lipoid disorders (preventive benefit must apply) |
Get the Full Picture for CPT 83721
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.